Published online before print March 31, 2003, doi: 10.1161/01.HYP.0000066289.17754.49
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2003;41:1072.)
© 2003 American Heart Association, Inc.
Scientific Contributions |
Interactions Between Leptin and the Human Sympathetic Nervous System
From the Baker Heart Research Institute and Alfred Baker Medical Unit, Alfred Hospital, Melbourne, Australia.
Correspondence to Prof Murray Esler, Baker Heart Research Institute, PO Box 6492 St Kilda Rd Central, Melbourne, Victoria 8008, Australia. E-mail murray.esler{at}baker.edu.au
Results from animal experimentation suggest a 2-way interaction between leptin and the sympathetic nervous system, with leptin causing sympathetic activation and conversely, with the sympathetic system exercising regulatory feedback inhibition over leptin release. We have now tested this hypothesis in humans. In the absence of results from leptin infusions, to test for sympathetic stimulation of leptin release, we sought a quantitative naturalistic linkage of sympathetic activity with leptin plasma concentration across a broad range of leptin values in men of widely differing adiposity. Renal norepinephrine spillover was correlated with plasma leptin (r=0.628, P<0.01), but other measures of sympathoadrenal function did not. To test for sympathetic and adrenomedullary inhibition of leptin release, we studied clinical models of high sympathetic tone, heart failure, and essential hypertension, in which lowered plasma leptin levels might have been expected but were not found; a model of low sympathetic activity, pure autonomic failure, in which plasma leptin level was normal (6.1±1.2 vs 12.8±3.1 ng/mL in healthy subjects); and a clinical model of reduced epinephrine secretion, healthy aging, in which plasma leptin level again was normal (5.7±1.1 ng/mL vs 4.0±0.9 ng/mL in men >60 years and <35 years, respectively). Paradoxically, leptin concentration was elevated in heart failure, caused entirely by reduced renal clearance of leptin release, 142.0±30.5 mL/min, compared with 56.9±18.9 mL/min (P<0.05). These results provide some support for the view that leptin stimulates the sympathetic nervous system, at least for renal sympathetic outflow, but do not confirm the concept of regulatory feedback inhibition of leptin release by the sympathetic nervous system.
Key Words: leptin • nervous system, sympathetic renal • heart failure • hypertension, essential • autonomic nervous system • aging • obesity
This article has been cited by other articles:
 |
|
 |
|
  E. J. Belin de Chantemele, K. Muta, J. Mintz, M. L. Tremblay, M. B. Marrero, D. J. Fulton, and D. W. Stepp Protein Tyrosine Phosphatase 1B, a Major Regulator of Leptin-Mediated Control of Cardiovascular Function Circulation, September 1, 2009; 120(9): 753 - 763. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Beddhu, S. U. Nigwekar, X. Ma, and T. Greene Associations of resting heart rate with insulin resistance, cardiovascular events and mortality in chronic kidney disease Nephrol. Dial. Transplant., August 1, 2009; 24(8): 2482 - 2488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Michaels, G. A. Eppel, S. L. Burke, G. A. Head, J. Armitage, J. F. Carroll, S. C. Malpas, and R. G. Evans Altered responsiveness of the kidney to activation of the renal nerves in fat-fed rabbits Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2009; 296(6): R1889 - R1896. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Galletti, L. D'Elia, G. Barba, A. Siani, F. P. Cappuccio, E. Farinaro, R. Iacone, O. Russo, D. De Palma, R. Ippolito, et al. High-Circulating Leptin Levels Are Associated with Greater Risk of Hypertension in Men Independently of Body Mass and Insulin Resistance: Results of an Eight-Year Follow-Up Study J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3922 - 3926. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. V. Agapitov, M. L. d. G. Correia, C. A. Sinkey, and W. G. Haynes Dissociation Between Sympathetic Nerve Traffic and Sympathetically Mediated Vascular Tone in Normotensive Human Obesity Hypertension, October 1, 2008; 52(4): 687 - 695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Kristal, K. B. Arnold, J. M. Schenk, M. L. Neuhouser, P. Goodman, D. F. Penson, and I. M. Thompson Dietary Patterns, Supplement Use, and the Risk of Symptomatic Benign Prostatic Hyperplasia: Results from the Prostate Cancer Prevention Trial Am. J. Epidemiol., April 15, 2008; 167(8): 925 - 934. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Lambert, N. Straznicky, M. Schlaich, M. Esler, T. Dawood, E. Hotchkin, and G. Lambert Differing Pattern of Sympathoexcitation in Normal-Weight and Obesity-Related Hypertension Hypertension, November 1, 2007; 50(5): 862 - 868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Katagiri, T. Yamada, and Y. Oka Adiposity and Cardiovascular Disorders: Disturbance of the Regulatory System Consisting of Humoral and Neuronal Signals Circ. Res., July 6, 2007; 101(1): 27 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Diepvens, K. R. Westerterp, and M. S. Westerterp-Plantenga Obesity and thermogenesis related to the consumption of caffeine, ephedrine, capsaicin, and green tea Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2007; 292(1): R77 - R85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Esler, N. Straznicky, N. Eikelis, K. Masuo, G. Lambert, and E. Lambert Mechanisms of Sympathetic Activation in Obesity-Related Hypertension Hypertension, November 1, 2006; 48(5): 787 - 796. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Janke, S. Engeli, M. Boschmann, F. Adams, J. Bohnke, F. C. Luft, A. M. Sharma, and J. Jordan Retinol-binding protein 4 in human obesity. Diabetes, October 1, 2006; 55(10): 2805 - 2810. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Esler and N. Eikelis Is obstructive sleep apnea the cause of sympathetic nervous activation in human obesity? J Appl Physiol, January 1, 2006; 100(1): 11 - 12. [Full Text] [PDF]
|
|
|
|
|
|
N. E. Straznicky, E. A. Lambert, G. W. Lambert, K. Masuo, M. D. Esler, and P. J. Nestel Effects of Dietary Weight Loss on Sympathetic Activity and Cardiac Risk Factors Associated with the Metabolic Syndrome J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 5998 - 6005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Eikelis and M. Esler The neurobiology of human obesity Exp Physiol, September 1, 2005; 90(5): 673 - 682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Grassi, A. Facchini, F. Q. Trevano, R. Dell'Oro, F. Arenare, F. Tana, G. Bolla, A. Monzani, M. Robuschi, and G. Mancia Obstructive Sleep Apnea-Dependent and -Independent Adrenergic Activation in Obesity Hypertension, August 1, 2005; 46(2): 321 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Rahmouni, D. A. Morgan, G. M. Morgan, A. L. Mark, and W. G. Haynes Role of Selective Leptin Resistance in Diet-Induced Obesity Hypertension Diabetes, July 1, 2005; 54(7): 2012 - 2018. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Rahmouni, M. L.G. Correia, W. G. Haynes, and A. L. Mark Obesity-Associated Hypertension: New Insights Into Mechanisms Hypertension, January 1, 2005; 45(1): 9 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Eikelis, G. Lambert, G. Wiesner, D. Kaye, M. Schlaich, M. Morris, J. Hastings, F. Socratous, and M. Esler Extra-adipocyte leptin release in human obesity and its relation to sympathoadrenal function Am J Physiol Endocrinol Metab, May 1, 2004; 286(5): E744 - E752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. F. DiBona The Sympathetic Nervous System and Hypertension: Recent Developments Hypertension, February 1, 2004; 43(2): 147 - 150. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Rahmouni and W. G. Haynes Leptin and the Cardiovascular System Recent Prog. Horm. Res., January 1, 2004; 59(1): 225 - 244. [Abstract] [Full Text]
|
|